Biotechnology

(redirected from biotech)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.

Biotechnology

The use of living things, such as one-cell organisms, in technological innovations. Biotechnology has particular applications in medicine, agriculture, engineering, and similar fields. Biotech organizations may make and market their own products, or they may be departments within another company, such as a pharmaceutical corporation.
References in periodicals archive ?
Public biotech companies that are constantly raising capital usually do so by entering into private securities offerings and later registering these securities with the SEC.
New Biotech Tools for a Cleaner Environment" is the first report to provide new industrial biotech projections for environmental improvement and energy conservation based on data from the U.
The biotech companies that have prospered through the recent recession have been those firms with existing, revenue-generating products.
In recent years, venture capitalists have invested in start-up biotech companies two years before they went public.
The following are among the key findings and figures in the Biotech Report:
Contact Jack Cecil: talk to him about the plans to turn WNC into the next biotech lab: Jack Cecil, President Biltmore Farms, Inc.
Our approach to bringing a biotech product to market has changed based on the introduction of biotech in other commodities," says Kelly Claus, a public affairs official for Monsanto, St.
An anonymous e-mail message recently sent to growers of biotech crops declared: "All of a sudden 'venture capitalist' scum realize that biotechnology is not such a great investment and they flee with their bags of cash with them.
But the decision marked the company's determination to grapple with issues that other maturing biotech firms are now beginning to confront.
a prominent area research facility, now called the Plant Biotech Institute, which dates to the early 1900s; and
The jury found that in 1984, Bio-Rad began selling components specially designed to be used in the process, and encouraged its customers to use the process, knowing that its competitor Pharmacia Biotech held a patent prohibiting such activities.
Elixir has developed expertise and a broad IP portfolio of more than twenty Sirtuin patents and patent applications which include coverage of small molecule SIRT1 inhibitors and activators, while Siena Biotech has developed over the years internal technological platforms and expertise in advanced research on Huntington's disease and optimization of targeted small molecules against neurodegenerative disorders.